<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36295554</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1648-9144</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>Medicina (Kaunas, Lithuania)</Title><ISOAbbreviation>Medicina (Kaunas)</ISOAbbreviation></Journal><ArticleTitle>Transitional Changes in Fatigue-Related Symptoms Due to Long COVID: A Single-Center Retrospective Observational Study in Japan.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1393</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medicina58101393</ELocationID><Abstract><AbstractText>Background and Objectives: Changes in post COVID-19 condition (PCC) characteristics caused by viral variants have yet to be clarified. We aimed to characterize the differences between clinical backgrounds and manifestations in long COVID patients who were infected with the Delta variant and those who were infected with the Omicron variants. Materials and Methods: This study was a single-center retrospective observational study for patients who visited our COVID-19 aftercare outpatient clinic (CAC) established in Okayama University Hospital (Japan) during the period from 15 February 2021 to 15 July 2022. We classified the onset of COVID-19 in the patients into three groups, the preceding, Delta-dominant, and Omicron-dominant periods, based on the prevalent periods of the variants in our prefecture. Results: In a total of 353 patients, after excluding 8 patients, 110, 130, and 113 patients were classified into the preceding, Delta-dominant, and Omicron-dominant periods, respectively. Patients infected in the Omicron-dominant period had significantly fewer hospitalizations, milder illnesses, more vaccinations and earlier visit to the CAC than did patients infected in the Delta-dominant period. Patients infected in the Omicron-dominant period had significantly lower frequencies of dysosmia (12% vs. 45%, ** p &lt; 0.01), dysgeusia (14% vs. 40%, ** p &lt; 0.01) and hair loss (7% vs. 28%, ** p &lt; 0.01) but had higher frequencies of fatigue (65% vs. 50%, * p &lt; 0.05), insomnia (26% vs. 13%, * p &lt; 0.05) and cough (20% vs. 7%, ** p &lt; 0.01) than did patients infected in the Delta-dominant period. Conclusions: The transitional changes in long COVID symptoms caused by the two variants were characterized.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakano</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-9972-791X</Identifier><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otsuka</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-6015-6128</Identifier><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honda</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sunada</LastName><ForeName>Naruhiko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tokumasu</LastName><ForeName>Kazuki</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-9513-6864</Identifier><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakurada</LastName><ForeName>Yasue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuda</LastName><ForeName>Yui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Toru</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ochi</LastName><ForeName>Kanako</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Education in Medicine and Health Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagiya</LastName><ForeName>Hideharu</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5086-1891</Identifier><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kataoka</LastName><ForeName>Hitomi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ueda</LastName><ForeName>Keigo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otsuka</LastName><ForeName>Fumio</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-7014-9095</Identifier><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Medicina (Kaunas)</MedlineTA><NlmUniqueID>9425208</NlmUniqueID><ISSNLinking>1010-660X</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Omicron variant</Keyword><Keyword MajorTopicYN="N">and post COVID-19 condition</Keyword><Keyword MajorTopicYN="N">dysgeusia</Keyword><Keyword MajorTopicYN="N">dysosmia</Keyword><Keyword MajorTopicYN="N">myalgic encephalomyelitis/chronic fatigue syndrome</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>27</Day><Hour>1</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36295554</ArticleId><ArticleId IdType="pmc">PMC9611667</ArticleId><ArticleId IdType="doi">10.3390/medicina58101393</ArticleId><ArticleId IdType="pii">medicina58101393</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V., WHO Clinical Case Definition Working Group on Post-COVID-19 Condition A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2022;22:e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi A., Bernabei R., Landi F., Gemelli Against COVID-19 Post-Acute Care Study Group Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324:603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering A.V., van Zon S.K.R., Olde Hartman T.C., Rosmalen J.G.M., Lifelines Corona Research I. Persistence of somatic symptoms after COVID-19 in the Netherlands: An observational cohort study. Lancet. 2022;400:452&#x2013;461. doi: 10.1016/S0140-6736(22)01214-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01214-4</ArticleId><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Otsuka Y., Tokumasu K., Nakano Y., Honda H., Sakurada Y., Sunada N., Omura D., Hasegawa K., Hagiya H., Obika M., et al. Clinical Characteristics of Japanese Patients Who Visited a COVID-19 Aftercare Clinic for Post-Acute Sequelae of COVID-19/Long COVID. Cureus. 2021;13:e18568. doi: 10.7759/cureus.18568.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.18568</ArticleId><ArticleId IdType="pmc">PMC8571943</ArticleId><ArticleId IdType="pubmed">34760415</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha L.B., Foster C., Rawlinson W., Tedla N., Bull R.A. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission. Rev. Med. Virol. 2022;32:e2381. doi: 10.1002/rmv.2381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2381</ArticleId><ArticleId IdType="pmc">PMC9349777</ArticleId><ArticleId IdType="pubmed">35856385</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C., Valdes A.M., Polidori L., Antonelli M., Penamakuri S., Nogal A., Louca P., May A., Figueiredo J.C., Hu C., et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: A prospective observational study from the ZOE COVID Study. Lancet. 2022;399:1618&#x2013;1624. doi: 10.1016/S0140-6736(22)00327-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00327-0</ArticleId><ArticleId IdType="pmc">PMC8989396</ArticleId><ArticleId IdType="pubmed">35397851</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M., Pujol J.C., Spector T.D., Ourselin S., Steves C.J. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399:2263&#x2013;2264. doi: 10.1016/S0140-6736(22)00941-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Sillett R., Zhu L., Mendel J., Camplisson I., Dercon Q., Harrison P.J. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: An analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry. 2022;9:815&#x2013;827. doi: 10.1016/S2215-0366(22)00260-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(22)00260-7</ArticleId><ArticleId IdType="pmc">PMC9385200</ArticleId><ArticleId IdType="pubmed">35987197</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokumasu K., Honda H., Sunada N., Sakurada Y., Matsuda Y., Yamamoto K., Nakano Y., Hasegawa T., Yamamoto Y., Otsuka Y., et al. Clinical Characteristics of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Diagnosed in Patients with Long COVID. Medicina. 2022;58:850. doi: 10.3390/medicina58070850.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina58070850</ArticleId><ArticleId IdType="pmc">PMC9325226</ArticleId><ArticleId IdType="pubmed">35888568</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakurada Y., Sunada N., Honda H., Tokumasu K., Otsuka Y., Nakano Y., Hanayama Y., Furukawa M., Hagiya H., Otsuka F. Serial Changes of Long COVID Symptoms and Clinical Utility of Serum Antibody Titers for Evaluation of Long COVID. J. Clin. Med. 2022;11:1309. doi: 10.3390/jcm11051309.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11051309</ArticleId><ArticleId IdType="pmc">PMC8911256</ArticleId><ArticleId IdType="pubmed">35268400</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto Y., Otsuka Y., Sunada N., Tokumasu K., Nakano Y., Honda H., Sakurada Y., Hagiya H., Hanayama Y., Otsuka F. Detection of Male Hypogonadism in Patients with Post COVID-19 Condition. J. Clin. Med. 2022;11:1955. doi: 10.3390/jcm11071955.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11071955</ArticleId><ArticleId IdType="pmc">PMC8999458</ArticleId><ArticleId IdType="pubmed">35407562</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunada N., Honda H., Nakano Y., Yamamoto K., Tokumasu K., Sakurada Y., Matsuda Y., Hasegawa T., Otsuka Y., Obika M., et al. Hormonal trends in patients suffering from long COVID symptoms. Endocr. J. 2022:EJ22-0093. doi: 10.1507/endocrj.EJ22-0093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1507/endocrj.EJ22-0093</ArticleId><ArticleId IdType="pubmed">35491089</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah W., Hillman T., Playford E.D., Hishmeh L. Managing the long term effects of covid-19: Summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136. doi: 10.1136/bmj.n136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n136</ArticleId><ArticleId IdType="pubmed">33483331</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato Y. Case Management of COVID-19 (Secondary Version) JMA J. 2021;4:191&#x2013;197. doi: 10.31662/jmaj.2021-0036.</Citation><ArticleIdList><ArticleId IdType="doi">10.31662/jmaj.2021-0036</ArticleId><ArticleId IdType="pmc">PMC8355701</ArticleId><ArticleId IdType="pubmed">34414312</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda Y. Investigation of the freely available easy-to-use software &#x2018;EZR&#x2019; for medical statistics. Bone Marrow Transplant. 2013;48:452&#x2013;458. doi: 10.1038/bmt.2012.244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2012.244</ArticleId><ArticleId IdType="pmc">PMC3590441</ArticleId><ArticleId IdType="pubmed">23208313</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda K., Straus S.E., Hickie I., Sharpe M.C., Dobbins J.G., Komaroff A. The chronic fatigue syndrome: A comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann. Intern Med. 1994;121:953&#x2013;959. doi: 10.7326/0003-4819-121-12-199412150-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-121-12-199412150-00009</ArticleId><ArticleId IdType="pubmed">7978722</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers B.M., Jain A.K., De Meirleir K.L., Peterson D.L., Klimas N.G., Lerner A.M., Bested A.C., Flor-Henry P., Joshi P., Powles A.C.P., et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. J. Chronic Fatigue Syndr. 2003;11:7&#x2013;115. doi: 10.1300/J092v11n01_02.</Citation><ArticleIdList><ArticleId IdType="doi">10.1300/J092v11n01_02</ArticleId></ArticleIdList></Reference><Reference><Citation>Clayton E.W. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: An IOM report on redefining an illness. JAMA. 2015;313:1101&#x2013;1102. doi: 10.1001/jama.2015.1346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.1346</ArticleId><ArticleId IdType="pubmed">25668027</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui K.P.Y., Ho J.C.W., Cheung M.C., Ng K.C., Ching R.H.H., Lai K.L., Kam T.T., Gu H., Sit K.Y., Hsin M.K.Y., et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature. 2022;603:715&#x2013;720. doi: 10.1038/s41586-022-04479-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04479-6</ArticleId><ArticleId IdType="pubmed">35104836</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai K., Yamano T., Nishi S., Nishi R., Nishi T., Tanaka H., Tsunoda T., Yoshimoto S., Tanaka A., Hiromatsu K., et al. Epipharyngeal Abrasive Therapy (EAT) Has Potential as a Novel Method for Long COVID Treatment. Viruses. 2022;14:907. doi: 10.3390/v14050907.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14050907</ArticleId><ArticleId IdType="pmc">PMC9147901</ArticleId><ArticleId IdType="pubmed">35632649</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara L.J., Izquierdo E., Medina G. Is the immune neuroendocrine system the connection between epipharyngitis and chronic fatigue syndrome induced by HPV vaccine?: Editorial. Immunol. Res. 2017;65:5&#x2013;7. doi: 10.1007/s12026-016-8854-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-016-8854-2</ArticleId><ArticleId IdType="pubmed">27605126</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J., Peng P., Cao X., Wu K., Chen J., Wang K., Tang N., Huang A.L. Increased immune escape of the new SARS-CoV-2 variant of concern Omicron. Cell Mol. Immunol. 2022;19:293&#x2013;295. doi: 10.1038/s41423-021-00836-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00836-z</ArticleId><ArticleId IdType="pmc">PMC8749347</ArticleId><ArticleId IdType="pubmed">35017716</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Sevilla J.J., Guerri-Fernadez R., Bertran Recasens B. Is There Less Alteration of Smell Sensation in Patients With Omicron SARS-CoV-2 Variant Infection? Front. Med. 2022;9:852998. doi: 10.3389/fmed.2022.852998.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.852998</ArticleId><ArticleId IdType="pmc">PMC9039252</ArticleId><ArticleId IdType="pubmed">35492353</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan B.K.J., Han R., Zhao J.J., Tan N.K.W., Quah E.S.H., Tan C.J., Chan Y.H., Teo N.W.Y., Charn T.C., See A., et al. Prognosis and persistence of smell and taste dysfunction in patients with covid-19: Meta-analysis with parametric cure modelling of recovery curves. BMJ. 2022;378:e069503. doi: 10.1136/bmj-2021-069503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069503</ArticleId><ArticleId IdType="pmc">PMC9326326</ArticleId><ArticleId IdType="pubmed">35896188</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H., Zhong L., Deng J., Peng J., Dan H., Zeng X., Li T., Chen Q. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int. J. Oral Sci. 2020;12:8. doi: 10.1038/s41368-020-0074-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41368-020-0074-x</ArticleId><ArticleId IdType="pmc">PMC7039956</ArticleId><ArticleId IdType="pubmed">32094336</ArticleId></ArticleIdList></Reference><Reference><Citation>Czech T., Sugihara S., Nishimura Y. Characteristics of hair loss after COVID-19: A systematic scoping review. J. Cosmet. Dermatol. 2022;21:3655&#x2013;3662. doi: 10.1111/jocd.15218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocd.15218</ArticleId><ArticleId IdType="pmc">PMC9349634</ArticleId><ArticleId IdType="pubmed">35801366</ArticleId></ArticleIdList></Reference><Reference><Citation>Otsuka Y., Nakano Y., Hagiya H., Tokumasu K., Otsuka F. Recovery From Alopecia After COVID-19. Cureus. 2022;14:e21160. doi: 10.7759/cureus.21160.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.21160</ArticleId><ArticleId IdType="pmc">PMC8831424</ArticleId><ArticleId IdType="pubmed">35165610</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwack M.H., Ahn J.S., Kim M.K., Kim J.C., Sung Y.K. Dihydrotestosterone-inducible IL-6 inhibits elongation of human hair shafts by suppressing matrix cell proliferation and promotes regression of hair follicles in mice. J. Investig. Dermatol. 2012;132:43&#x2013;49. doi: 10.1038/jid.2011.274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jid.2011.274</ArticleId><ArticleId IdType="pubmed">21881585</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson E.J., Williams D.M., Walker A.J., Mitchell R.E., Niedzwiedz C.L., Yang T.C., Huggins C.F., Kwong A.S.F., Silverwood R.J., Di Gessa G., et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat. Commun. 2022;13:3528. doi: 10.1038/s41467-022-30836-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30836-0</ArticleId><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>